CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed ...

Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled for ...

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it ...

Leqvio (inclisiran) may cause injection site reactions, including bruising, pain, discoloration, itchiness, and a burning or prickling sensation at the injection site. In addition to injection site ...